



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/582,393

12/26/2006

Wolfgang Kranewitter

GRE-106us

1617

23410 7590 01/15/2009
Vista IP Law Group LLP
2040 MAIN STREET, 9TH FLOOR
IRVINE, CA 92614

EXAMINER

WOOLWINE, SAMUEL C

ART UNIT

PAPER NUMBER

1637

MAIL DATE

DELIVERY MODE

01/15/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Response to Amendment

In response to the amendment filed 12/17/2008, it is noted that the claims do not comply with the rules for biological sequences set forth in 37 CFR 1.821. Specifically, paragraph (c) which states in part (emphasis provided):

Patent applications which contain disclosures of nucleotide and /or amino acid sequences must contain, as a separate part of the disclosure, a paper copy disclosing the nucleotide and /or amino acid sequences and associated information using the symbols and format in accordance with the requirements of §§ 1.822 and 1.823. This paper copy is hereinafter referred to as the "Sequence Listing." Each sequence disclosed must appear separately in the "Sequence Listing." Each sequence set forth in the "Sequence Listing" shall be assigned a separate sequence identifier.

Furthermore, paragraph (d) states:

Where the description or claims of a patent application discuss a sequence that is set forth in the "Sequence Listing" in accordance with paragraph (c) of this section, reference must be made to the sequence by use of the sequence identifier, preceded by "SEQ ID NO:" in the text of the description or claims, even if the sequence is also embedded in the text of the description or claims of the patent application.

Claims 1 and 2 recite sequences 5'-CARGCIAAAWWKTDAARGAYTGTG-3' and 5'-CARGCIAAATATKTRAAAGATTGTG-3' respectively, which have no SEQ ID NOs. In addition, these sequences are not found in the sequence listing. While it is appreciated that these sequences differ from SEQ ID NOs 1 and 2, respectively, by only a single position (they have I at position 6 rather than N), they are still different sequences and are therefore required to be in the Sequence Listing, have their own SEQ ID NOs, and be designated using those SEQ ID NOs wherever they appear (specification, drawings, claims, etc.).

Applicant is required to submit a complete sequence listing, computer-readable form, a statement as required by 37 CFR 1.821(f), and to amend the disclosure as

Art Unit: 1637

required (including the claims) using the proper SEQ ID NOs wherever the sequences appear.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCES RULES, 37 CFR 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAMUEL WOOLWINE whose telephone number is (571)272-1144. The examiner can normally be reached on Mon-Fri 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Samuel Woolwine/
Examiner, Art Unit 1637